Released Feb 4, 2026, before the open
10-K filed Feb 12, 2026, 43 days after period end · 0000059478-26-000013
derived · Computed from the longer spans the company filed.
Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth-quarter of 2025 and provided 2026 financial guidance.
The release| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $19.29B | $13.53B | $9.35B | $7.30B |
Eli Lilly & Co · CIK 59478 · Engraved from SEC EDGAR
| Net Income | $6.64B | $4.41B | $2.19B | $1.94B |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Eli Lilly and Company announced its fourth-quarter 2025 financial results and provided 2026 financial guidance.¶1
Fourth-quarter 2025 revenue increased 43% to $19.3 billion, driven by volume growth from Mounjaro and Zepbound.¶2¶3
Fourth-quarter 2025 EPS increased by 51% to $7.39 on a reported basis and by 42% to $7.54 on a non-GAAP basis.¶4
Lilly issued 2026 guidance for revenue of $80 billion to $83 billion and non-GAAP EPS of $33.50 to $35.00.¶5